NovaBridge shareholders remove director Xin Liu

NovaBridge Biosciences shareholders approved an ordinary resolution to remove director Xin Liu at the 2026 AGM, with quorum reached at 44.8% of shares outstanding.

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) reports the voting results of its 2026 annual general meeting of shareholders held on September 8, 2026 in Shanghai. Holders of 121,294,288 shares, representing approximately 44.8% of the 270,740,383 shares outstanding as of July 27, 2026, were present in person or by proxy, satisfying the quorum requirement under the company’s memorandum and articles of association.

Shareholders approved an ordinary resolution to remove Ms. Xin Liu from her position as a director of the company with immediate effect upon passage of the resolution. The resolution received 107,925,508 votes for, 13,313,327 votes against and 55,453 abstentions. The report also states that this information is incorporated by reference into NovaBridge’s effective registration statements on Form F-3 and multiple Form S-8 filings.

Key Figures

Shares represented at AGM: 121,294,288 shares Ordinary shares present directly: 6,078,571 shares Ordinary shares represented by ADSs: 115,215,717 shares +5 more

8 metrics

Shares represented at AGM 121,294,288 shares Shares present in person or by proxy at the September 8, 2026 AGM

Ordinary shares present directly 6,078,571 shares Ordinary shares held directly and present at the AGM

Ordinary shares represented by ADSs 115,215,717 shares Ordinary shares represented by American depositary shares at the AGM

Shares outstanding on record date 270,740,383 shares Total shares outstanding as of July 27, 2026 record date

Quorum percentage 44.8% Portion of outstanding shares represented at AGM, constituting a quorum

Votes for removal of Xin Liu 107,925,508 votes Votes in favor of ordinary resolution to remove director Xin Liu

Votes against removal of Xin Liu 13,313,327 votes Votes against the resolution to remove director Xin Liu

Abstentions on removal of Xin Liu 55,453 votes Abstaining votes on the resolution to remove director Xin Liu

Key Terms

American depositary shares, ordinary resolution, quorum, incorporated by reference

4 terms

American depositary shares financial

"115,215,717 ordinary shares represented by American depositary shares (“ADSs”)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ordinary resolution regulatory

"The shareholders approved as an ordinary resolution that Ms. Xin Liu be removed"

An ordinary resolution is a decision made by shareholders at a company meeting that is approved when more than half of the votes cast are in favor. Think of it like a household vote where a majority decides routine matters — it covers everyday corporate actions such as approving directors, routine policy changes, or distributions, and matters to investors because these majority-approved choices shape governance, management authority, and the company’s near-term direction.

quorum regulatory

"representing approximately 44.8% ... and therefore constituting a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

incorporated by reference regulatory

"The information set forth in this report on Form 6-K shall be deemed to be incorporated by reference"

FAQ

What key decision was made at NovaBridge Biosciences (NBP) 2026 AGM?

Shareholders approved an ordinary resolution to remove Ms. Xin Liu from her position as a director of NovaBridge Biosciences, effective immediately upon passage of the resolution, based on the voting results reported for the September 8, 2026 annual general meeting.

How many NovaBridge Biosciences (NBP) shares were represented at the 2026 AGM?

Holders of 121,294,288 shares were present in person or by proxy at the AGM. This included 6,078,571 ordinary shares and 115,215,717 ordinary shares represented by ADSs, providing the basis for the reported quorum.

What percentage of NovaBridge Biosciences (NBP) shares did the AGM attendance represent?

The 121,294,288 shares represented at the AGM accounted for approximately 44.8% of the company’s 270,740,383 shares outstanding as of the record date of July 27, 2026, and this level of participation constituted a quorum under the company’s governing documents.

What were the detailed voting results on removing director Xin Liu at NBP?

The resolution to remove director Xin Liu received 107,925,508 votes for, 13,313,327 votes against, and 55,453 abstentions. The company states that shareholders approved the resolution as an ordinary resolution, making the removal effective immediately.

How does this 6-K affect NovaBridge Biosciences (NBP) registration statements?

The company states that the information in this Form 6-K is incorporated by reference into its Registration Statement on Form F-3 (File No. 333-286954) and several Form S-8 registration statements, becoming part of those filings from the date this 6-K is furnished.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:00 AM Accepted by SEC EDGAR 09/08/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

Voting Results of 2026 Annual General Meeting

NovaBridge Biosciences (the “Company”) held its annual general meeting of shareholders (the “AGM”) on September 8, 2026 at 10:00 a.m. (Shanghai time) at the Company’s Shanghai office, 38F, AIA Tower, No. 866 Dongchangzhi Road, Shanghai, China.

Holders of 121,294,288 shares of the Company, consisting of 6,078,571 ordinary shares and 115,215,717 ordinary shares represented by American depositary shares (“ADSs”), were present in person or by proxy at the AGM, representing approximately 44.8% of the total 270,740,383 shares outstanding as of the record date of July 27, 2026, and therefore constituting a quorum under the Company’s seventh amended and restated memorandum and articles of association.

The final voting results for the matter submitted to a vote of shareholders at the AGM are as follows:

The shareholders approved as an ordinary resolution that Ms. Xin Liu be removed from her position as a director of the Company with immediate effect upon passing of the resolution.

For	Against	Abstain
107,925,508	13,313,327	55,453

Incorporation by Reference

The information set forth in this report on Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842, File No. 333-290195 and File No. 333-298369) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NovaBridge Biosciences
	By	:	/s/ Kyler Lei
	Name	:	Kyler Lei
	Title	:	Chief Financial Officer

Date: September 8, 2026